Cargando…
Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3
Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574513/ https://www.ncbi.nlm.nih.gov/pubmed/37836759 http://dx.doi.org/10.3390/molecules28196916 |
_version_ | 1785120711902232576 |
---|---|
author | Tasso, Bruno Mattioli, Laura Beatrice Tonelli, Michele Boido, Vito Chiarini, Alberto Sparatore, Fabio Budriesi, Roberta |
author_facet | Tasso, Bruno Mattioli, Laura Beatrice Tonelli, Michele Boido, Vito Chiarini, Alberto Sparatore, Fabio Budriesi, Roberta |
author_sort | Tasso, Bruno |
collection | PubMed |
description | Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC(50) = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation. |
format | Online Article Text |
id | pubmed-10574513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105745132023-10-14 Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 Tasso, Bruno Mattioli, Laura Beatrice Tonelli, Michele Boido, Vito Chiarini, Alberto Sparatore, Fabio Budriesi, Roberta Molecules Article Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC(50) = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation. MDPI 2023-10-03 /pmc/articles/PMC10574513/ /pubmed/37836759 http://dx.doi.org/10.3390/molecules28196916 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tasso, Bruno Mattioli, Laura Beatrice Tonelli, Michele Boido, Vito Chiarini, Alberto Sparatore, Fabio Budriesi, Roberta Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title | Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title_full | Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title_fullStr | Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title_full_unstemmed | Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title_short | Further Quinolizidine Derivatives as Antiarrhythmic Agents- 3 |
title_sort | further quinolizidine derivatives as antiarrhythmic agents- 3 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574513/ https://www.ncbi.nlm.nih.gov/pubmed/37836759 http://dx.doi.org/10.3390/molecules28196916 |
work_keys_str_mv | AT tassobruno furtherquinolizidinederivativesasantiarrhythmicagents3 AT mattiolilaurabeatrice furtherquinolizidinederivativesasantiarrhythmicagents3 AT tonellimichele furtherquinolizidinederivativesasantiarrhythmicagents3 AT boidovito furtherquinolizidinederivativesasantiarrhythmicagents3 AT chiarinialberto furtherquinolizidinederivativesasantiarrhythmicagents3 AT sparatorefabio furtherquinolizidinederivativesasantiarrhythmicagents3 AT budriesiroberta furtherquinolizidinederivativesasantiarrhythmicagents3 |